A single infusion that appears to repair heart damage represents something genuinely new.
For the roughly one in fifty thousand Americans living with Friedreich ataxia, medicine has long offered little more than the management of decline. Now, a phase 1 trial published in JAMA Cardiology suggests that a single infusion of a healthy gene, carried into the heart by a harmless virus, may do what no approved treatment has yet achieved: address the disease at its genetic root and measurably reverse damage to the heart. It is a small study, an early chapter, but in a condition where the heart fails in nearly two-thirds of patients, even a foothold carries profound weight.
- Friedreich ataxia kills most of those it claims through heart failure, and until now no treatment has touched the underlying genetic cause.
- Seventeen patients received a single IV infusion of a virus carrying a healthy FXN gene — a therapy the human body has never before encountered in this form.
- Heart wall thickness decreased, frataxin protein levels rose in cardiac tissue, and markers of heart damage fell — measurable changes in the organ itself, not just theoretical signals.
- Four serious adverse events occurred but resolved, and three were linked to the immunosuppression drug rather than the gene therapy itself, preserving the safety profile.
- Whether neurological benefits are real, whether the therapy holds in sicker patients, and whether FDA approval follows all remain open questions driving the next phase of trials.
A rare inherited disorder called Friedreich ataxia begins with a single genetic error — a faulty FXN gene inherited from both parents — that robs the body's most energy-hungry organs of the protein they need to function. The heart and brain suffer most. Patients typically notice neurological symptoms first, but it is heart disease that proves fatal, claiming up to sixty-five percent of those affected. Only one FDA-approved drug exists, and it slows neurological decline without touching the genetic cause.
Dr. Ronald Crystal and his team at Weill Cornell Medicine took a different approach. They packaged a healthy copy of the FXN gene inside a harmless viral shell and delivered it to seventeen patients through a single one-hour infusion. The patients were monitored for up to three years across three dosage levels, with some enrolled through Weill Cornell and others through Lexeo Therapeutics, a company Crystal founded.
The results, published in JAMA Cardiology, were encouraging. Frataxin protein levels rose in cardiac tissue. The thickened heart walls that define the disease's cardiomyopathy began to shrink. Blood markers of heart damage fell. These were not projected improvements — they were measurable changes in the organ itself. Four serious adverse events occurred, all resolved, and most appeared linked to the immunosuppression drug rather than the therapy.
The neurological picture remains less clear. Some patients showed stabilization on standardized assessments, but Crystal acknowledged that whether the gene therapy reached the brain or skeletal muscle — or whether stabilization happened for unrelated reasons — is still unknown.
What follows is expansion. The trial enrolled mostly patients with early-stage disease; researchers now want to test the therapy across the full spectrum of severity, with FDA approval as the stated goal. For a condition that has offered patients almost no hope of altering its course, a single infusion that appears to repair heart damage is something genuinely new — and the questions that remain will define whether this early promise becomes a lasting one.
A small group of patients with a rare, inherited heart disease received an experimental treatment that their bodies had never encountered before—a virus carrying a healthy gene, delivered through an IV line. The results, published in JAMA Cardiology, suggest the therapy is safe and may actually slow the damage the disease inflicts on the heart. For people living with Friedreich ataxia cardiomyopathy, a condition that kills most of those who develop it, this represents the first real foothold in a disease that medicine has largely been unable to touch.
Friedreich ataxia strikes roughly one in fifty thousand Americans. It begins with a genetic mistake—a faulty copy of the FXN gene inherited from both parents. This gene normally produces a protein that helps cells generate energy. Without it, the organs that demand the most fuel suffer first. The brain and heart are the body's most energy-hungry systems, which is why the disease attacks both. Patients typically notice the neurological symptoms first: trouble with balance, walking, speech. But the heart disease is what kills them. In up to sixty-five percent of cases, a weakened, thickened heart muscle eventually fails. The FDA has approved only one drug for the condition, and it merely slows the neurological decline without addressing the underlying genetic cause.
Dr. Ronald Crystal and his team at Weill Cornell Medicine decided to try something different. They took the healthy FXN gene and packaged it inside an adeno-associated virus—a harmless viral shell designed to travel to the heart. Seventeen patients received a single one-hour infusion. Some came from a Weill Cornell study; others were treated by Lexeo Therapeutics, a company Crystal founded. The researchers tracked them for six to thirty-six months, testing three different doses.
The treatment proved safe. Four serious adverse events occurred, all of which resolved. Three were possibly tied to prednisone, an immunosuppression drug the patients took to prevent their immune systems from attacking the therapy. In the Lexeo cohort, heart biopsies taken before and three months after treatment showed that frataxin protein levels rose in cardiac tissue across all eight patients. MRI scans revealed that the left ventricular mass index—a measure of heart wall thickness—decreased. The thickened walls that characterize cardiomyopathy were actually shrinking. Blood levels of troponin I, a protein released when heart tissue is damaged, also fell. These are not theoretical improvements; they are measurable changes in the organ itself.
The neurological picture is murkier. Using a standardized assessment scale, researchers found that some neurological components of the disease stabilized in certain patients. But Crystal acknowledged the uncertainty: the gene therapy may have reached skeletal muscle or the brain, or the stabilization may have occurred for other reasons entirely. That question remains open.
What comes next is expansion. The current trial enrolled mostly patients with early-stage heart disease. The researchers want to test the therapy in people with more advanced cardiomyopathy, to see whether it works across the full spectrum of severity. The goal, Crystal said plainly, is FDA approval. For a disease that has offered patients almost no hope of slowing its progression, a single infusion that appears to repair heart damage represents something genuinely new. Whether it will hold up in larger trials, whether it will work in sicker patients, whether the neurological benefits will become clearer—these questions will shape the next chapter. But the first chapter, at least, has been written in a way that suggests the story might not end where everyone expected.
Notable Quotes
This is a fatal disease, but this is a potential therapy, and our goal is FDA approval.— Dr. Ronald G. Crystal, lead researcher, Weill Cornell Medicine
The two most energy-consuming organs in the body are your brain and the heart, so the disease is primarily a brain and heart disease.— Dr. Ronald G. Crystal
The Hearth Conversation Another angle on the story
Why does this particular disease attack the heart so aggressively?
The FXN gene makes a protein that helps cells produce energy. The heart is the most energy-demanding organ in the body. Without that protein, heart cells can't generate enough fuel to beat normally, so they enlarge and the walls thicken. Eventually the muscle fails.
And the virus—why is that the right delivery vehicle?
Adeno-associated viruses are small, they don't cause disease in humans, and they naturally home to the heart. You package the healthy gene inside, infuse it intravenously, and it travels where you need it to go. It's like a biological postal service.
The patients had to take prednisone to suppress their immune system. Doesn't that create its own problems?
It does. Three of the four serious adverse events in the trial were possibly linked to the prednisone. That's a trade-off the researchers had to make—without immunosuppression, the body would attack and destroy the viral vector before it could do its work. It's a problem they'll need to solve for wider use.
The neurological symptoms stabilized in some patients. Why is that unclear?
The gene therapy was designed to target the heart. But the FXN protein is needed everywhere—brain, spinal cord, skeletal muscle. If some neurological symptoms improved, it could mean the virus reached those tissues, or it could be coincidence. They simply don't know yet.
What would make you confident this actually works?
Larger trials in sicker patients. These seventeen people mostly had early heart disease. If the therapy shrinks thickened hearts in people with advanced cardiomyopathy, if it prevents heart failure, if those benefits hold up over years—then you have something real.